Testosterone Replacement Safety Gets FDA Panel Review As Lawsuits Pile Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Two advisory committees will discuss appropriate population for testosterone treatment and potential for adverse cardiovascular outcomes; product liability suits have been consolidated in Illinois federal court.
You may also be interested in...
Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.